Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagné(National Institutes of Health), Daniel C. Douek(National Institutes of Health)Nature CommunicationsAugust 12, 202410.1038/s41467-024-51046-wCited by 1SaveCiteExport RISWatch citationsRelated PapersSystemic Effects of Inflammation on Health during Chronic HIV Infection|Immunity|2013|835Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates|Nature Immunology|2024|45MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity|PLoS Pathogens|2016|30